Public articles linked to the same research event.
The Journal of asthma : official journal of the Association for the Care of Asthma Using the Japanese JAMDAS electronic medical records database, this retrospective observational study analyzed 32,258 patients with asthma who initiated fluticasone furoate/umeclidinium/vilanterol single-inhaler triple therapy between August 18, 2020 and December 31, 2024, extracting Asthma Control Test scores via structured query language and hospitalization and emergency transport data via a large language model, and assessed the proportion meeting the Japanese Practical Guidelines for Asthma Management 2024 clinical remission definition (oral corticosteroid-free, no exacerbations, ACT >= 23), treatment patterns, adherence and persistence at 3-month intervals up to 18 months; only 1.8-3.0%, 0.5-1.5% and 4.5-10.
Using the Japanese JAMDAS electronic medical records database, this retrospective observational study analyzed 32,258 patients with asthma who initiated fluticasone furoate/umeclidinium/vilanterol single-inhaler triple therapy between August 18, 2020 and December 31, 2024, extracting Asthma Control Test scores via structured query language and hospitalization and emergency transport data via a large language model, and assessed the proportion meeting the Japanese Practical Guidelines for Asthma Management 2024 clinical remission definition (oral corticosteroid-free, no exacerbations, ACT >= 23), treatment patterns, adherence and persistence at 3-month intervals up to 18 months; only 1.8-3.0%, 0.5-1.5% and 4.5-10.
Using the Japanese JAMDAS electronic medical records database, this retrospective observational study analyzed 32,258 patients with asthma who initiated fluticasone furoate/umeclidinium/vilanterol single-inhaler triple therapy between August 18, 2020 and December 31, 2024, extracting Asthma Control Test scores via structured query language and hospitalization and emergency transport data via a large language model, and assessed the proportion meeting the Japanese Practical Guidelines for Asthma Management 2024 clinical remission definition (oral corticosteroid-free, no exacerbations, ACT >= 23), treatment patterns, adherence and persistence at 3-month intervals up to 18 months; only 1.8-3.0%, 0.5-1.5% and 4.5-10.
Using the Japanese JAMDAS electronic medical records database, this retrospective observational study analyzed 32,258 patients with asthma who initiated fluticasone furoate/umeclidinium/vilanterol single-inhaler triple therapy between August 18, 2020 and December 31, 2024, extracting Asthma Control Test scores via structured query language and hospitalization and emergency transport data via a large language model, and assessed the proportion meeting the Japanese Practical Guidelines for Asthma Management 2024 clinical remission definition (oral corticosteroid-free, no exacerbations, ACT >= 23), treatment patterns, adherence and persistence at 3-month intervals up to 18 months; only 1.8-3.0%, 0.5-1.5% and 4.5-10.